$53.76
-0.75 (-1.38%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GPCR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional
Held by 10 tracked-famous managers (MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +5 more) · FINRA short interest 11.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)NCT07654361Percent change in body weight from BaselineRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Aleniglipron, Placebo | Obesity, Overweight, Chronic Weight Management | 3,600 | Sep 2028 | ≤ 773 d | 2026-08-10 |
| A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374Percent change in body weight from BaselineRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: aleniglipron, aleniglipron, aleniglipron, Placebo | Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus | 1,100 | Sep 2028 | ≤ 773 d | 2026-08-10 |
| Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588Incidence, severity and relationship of AEs/SAEsRandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Aleniglipron, Placebo | Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss | 58 | Sep 2026 | ≤ 42 d | 2026-04-27 |
| Aleniglipron Phase 2 Body Composition StudyNCT07169942Percent change in total body fat mass by DXARandomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: aleniglipron or placebo | Obesity, Overweight, or Chronic Weight Management | 71 | Aug 2026 | ≤ 12 d | 2026-03-03 |
| A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06703021Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo | Obesity, Overweight, Chronic Weight Management | 85 | 2026-01-12actual | — | 2026-04-28 |
| A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843Percent change in body weight from Baseline to Week 36Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron, Aleniglipron, Aleniglipron | Obesity, Overweight, or Chronic Weight Management | 230 | 2025-10-24actual | — | 2026-08-10 |
| Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusNCT05762471Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DMRandomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: GSBR-1290, Placebo | Overweight or Obesity, Type2 Diabetes Mellitus | 142 | 2024-04-11actual | — | 2024-04-25 |
| A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsNCT06139055Part 1: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) ParametersRandomized · Quadruple-masked · Treatment | Phase 1 | Unknown status | Drug: GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet) | Healthy Volunteers | 70 | Mar 2024 | — | 2024-02-15 |
| A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy ParticipantsNCT05893043Number of Participants With Adverse Events (AEs) and Serious AEsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: GSBR-1290 · Other: Placebo | Healthy Volunteers | 18 | 2023-06-28actual | — | 2023-07-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19